# Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

> **NCT01107886** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 18206 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01107886
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 18206 (ACTUAL)
- **Last updated:** 2014-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107886, "Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01107886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*